A synthetic cyclized antimicrobial peptide with potent effects against drug resistant skin pathogens

John Kerr  White; Soumitra  Mohanty; Taj Muhammad; Magdalena  de Arriba Sanchez de la Campa; Wael E Houssen; Natalia  Ferraz; Ulf Göransson; Annelie  Brauner

doi:10.1021/acsinfecdis.2c00598

A synthetic cyclized antimicrobial peptide with potent effects against drug resistant skin pathogens

John Kerr White, Soumitra Mohanty, Taj Muhammad, Magdalena de Arriba Sanchez de la Campa, Wael E Houssen, Natalia Ferraz, Ulf Göransson, Annelie Brauner^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

1 Downloads (Pure)

Abstract

Dermal infections requiring treatment are usually treated with conventional
antibiotics, but the rise of bacterial resistance to first-line antibiotics warrants alternative therapeutics. Here, we report that a backbone-cyclized antimicrobial peptide, CD4-PP, designed from the human host defence peptide LL-37, has strong direct antibacterial effects on antibiotic sensitive as well as resistant type strains and clinical isolates of common skin pathogens in low (and treatment with CD4-PP is able to clear bacterial infections in infected keratinocytes.
Additionally, CD4-PP treatment significantly reduces the wound area in a lawn of
keratinocytes infected with MRSA. In conclusion, CD4-PP has the potential to serve as a future drug treating wounds infected with antibiotic resistant bacteria.

Original language	English
Pages (from-to)	1056-1063
Number of pages	8
Journal	ACS Infectious Diseases
Volume	9
Issue number	5
Early online date	3 May 2023
DOIs	https://doi.org/10.1021/acsinfecdis.2c00598
Publication status	Published - 12 May 2023

Bibliographical note

Acknowledgments
We would like to thank Anna Blasi-Romero for helping with the set-up of the
initial scanning electron microscopy experiments. This project was partially supported by the Stiftelsen Olle Engkvist Byggmästare (AB 186 678), Region Stockholm (AB, ALF project 995080), a fellowship grant from the EPSRC (no. EP/S027246/1, W.E.H.), the Bo Rydin Foundation (no. F30/20; NF), the Swedish Research Council (# no. 2011-3403; UG); and Postdoctoral scholarship by Elisabeth and Alfred Ahlqvists Stiftelse, Apotekarsocieteten (TM). The graphical abstract was created with a BioRender standard academic license.

Keywords

Keratinocytes;
MRSA
synthetic antimicrobial peptide
LL-37
bactericidal peptide
Wound closure

Access to Document

10.1021/acsinfecdis.2c00598Licence: CC BY

White_etal_acsinfecdis_Synthetic_Cyclized_Antimicrobial_VOR
https://creativecommons.org/licenses/by/4.0/
Final published version, 5.41 MBLicence: CC BY

Cite this

@article{7a24f5e3276344e5ad73d7d369d281dd,

title = "A synthetic cyclized antimicrobial peptide with potent effects against drug resistant skin pathogens",

abstract = "Dermal infections requiring treatment are usually treated with conventionalantibiotics, but the rise of bacterial resistance to first-line antibiotics warrants alternative therapeutics. Here, we report that a backbone-cyclized antimicrobial peptide, CD4-PP, designed from the human host defence peptide LL-37, has strong direct antibacterial effects on antibiotic sensitive as well as resistant type strains and clinical isolates of common skin pathogens in low (and treatment with CD4-PP is able to clear bacterial infections in infected keratinocytes.Additionally, CD4-PP treatment significantly reduces the wound area in a lawn ofkeratinocytes infected with MRSA. In conclusion, CD4-PP has the potential to serve as a future drug treating wounds infected with antibiotic resistant bacteria.",

keywords = "Keratinocytes;, MRSA, synthetic antimicrobial peptide, LL-37, bactericidal peptide, Wound closure",

author = "White, {John Kerr} and Soumitra Mohanty and Taj Muhammad and {de Arriba Sanchez de la Campa}, Magdalena and Houssen, {Wael E} and Natalia Ferraz and Ulf G{\"o}ransson and Annelie Brauner",

note = "Acknowledgments We would like to thank Anna Blasi-Romero for helping with the set-up of the initial scanning electron microscopy experiments. This project was partially supported by the Stiftelsen Olle Engkvist Byggm{\"a}stare (AB 186 678), Region Stockholm (AB, ALF project 995080), a fellowship grant from the EPSRC (no. EP/S027246/1, W.E.H.), the Bo Rydin Foundation (no. F30/20; NF), the Swedish Research Council (# no. 2011-3403; UG); and Postdoctoral scholarship by Elisabeth and Alfred Ahlqvists Stiftelse, Apotekarsocieteten (TM). The graphical abstract was created with a BioRender standard academic license.",

year = "2023",

month = may,

day = "12",

doi = "10.1021/acsinfecdis.2c00598",

language = "English",

volume = "9",

pages = "1056--1063",

journal = "ACS Infectious Diseases",

issn = "2373-8227",

publisher = "American Chemical Society",

number = "5",

}

TY - JOUR

T1 - A synthetic cyclized antimicrobial peptide with potent effects against drug resistant skin pathogens

AU - White, John Kerr

AU - Mohanty, Soumitra

AU - Muhammad, Taj

AU - de Arriba Sanchez de la Campa, Magdalena

AU - Houssen, Wael E

AU - Ferraz, Natalia

AU - Göransson, Ulf

AU - Brauner, Annelie

N1 - Acknowledgments We would like to thank Anna Blasi-Romero for helping with the set-up of the initial scanning electron microscopy experiments. This project was partially supported by the Stiftelsen Olle Engkvist Byggmästare (AB 186 678), Region Stockholm (AB, ALF project 995080), a fellowship grant from the EPSRC (no. EP/S027246/1, W.E.H.), the Bo Rydin Foundation (no. F30/20; NF), the Swedish Research Council (# no. 2011-3403; UG); and Postdoctoral scholarship by Elisabeth and Alfred Ahlqvists Stiftelse, Apotekarsocieteten (TM). The graphical abstract was created with a BioRender standard academic license.

PY - 2023/5/12

Y1 - 2023/5/12

N2 - Dermal infections requiring treatment are usually treated with conventionalantibiotics, but the rise of bacterial resistance to first-line antibiotics warrants alternative therapeutics. Here, we report that a backbone-cyclized antimicrobial peptide, CD4-PP, designed from the human host defence peptide LL-37, has strong direct antibacterial effects on antibiotic sensitive as well as resistant type strains and clinical isolates of common skin pathogens in low (and treatment with CD4-PP is able to clear bacterial infections in infected keratinocytes.Additionally, CD4-PP treatment significantly reduces the wound area in a lawn ofkeratinocytes infected with MRSA. In conclusion, CD4-PP has the potential to serve as a future drug treating wounds infected with antibiotic resistant bacteria.

AB - Dermal infections requiring treatment are usually treated with conventionalantibiotics, but the rise of bacterial resistance to first-line antibiotics warrants alternative therapeutics. Here, we report that a backbone-cyclized antimicrobial peptide, CD4-PP, designed from the human host defence peptide LL-37, has strong direct antibacterial effects on antibiotic sensitive as well as resistant type strains and clinical isolates of common skin pathogens in low (and treatment with CD4-PP is able to clear bacterial infections in infected keratinocytes.Additionally, CD4-PP treatment significantly reduces the wound area in a lawn ofkeratinocytes infected with MRSA. In conclusion, CD4-PP has the potential to serve as a future drug treating wounds infected with antibiotic resistant bacteria.

KW - Keratinocytes;

KW - MRSA

KW - synthetic antimicrobial peptide

KW - LL-37

KW - bactericidal peptide

KW - Wound closure

U2 - 10.1021/acsinfecdis.2c00598

DO - 10.1021/acsinfecdis.2c00598

M3 - Article

SN - 2373-8227

VL - 9

SP - 1056

EP - 1063

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

IS - 5

ER -

A synthetic cyclized antimicrobial peptide with potent effects against drug resistant skin pathogens

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this